GRZAN Guatemala Service Model: Own Team and Licensed Local Partner Delivery
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
In Guatemala, GRZAN (Guorui Zhongan) operates a combined model of its own team plus a licensed local partner: the GRZAN registration team carries the qualitative determinations, dossier preparation, project management and submission follow-up, while a licensed Guatemalan partner (a distribuidora or droguería holding a Licencia Sanitaria) provides the registration holder eligibility and the local signatures. This model corresponds to the mandatory requirement of Article 5.1.13 of NT 37 on the qualifications of the registration holder, and to Article 5.1.2 on the signature of the local responsible professional. The division is not a packaging choice but a mapping of the legal requirements onto the parties best placed to satisfy them. The foreign manufacturer cannot, by itself, hold the local licence or sign locally, so any compliant delivery route must include a local licensed component; what the own-team side contributes is control of technical quality and continuity across markets. The model also determines how problems are handled: because the own team holds the dossier knowledge and the partner holds the local relationship, incidents, change filings and renewal actions each have a defined route from the outset, rather than being negotiated case by case.
2. Legal basis
The table below lists each step of the delivery model against the corresponding legal requirement and the article that imposes it. It is the reference for confirming, at project start, that every mandatory element of the filing has an owner in the model. The rows are ordered roughly as the filing itself proceeds, from holder eligibility and signatures through to the import stage, so the table can double as a sequencing guide for the project plan.
| Registration holder | Must be an establishment domiciled in the country holding a sanitary licence | Article 5.1.13 |
| Signature of the application form | Signed and stamped by a pharmaceutical chemist (devices) or pharmaceutical chemist / chemical biologist (reagents), with an embossed seal | Article 5.1.2; NT 40 Article 4.1.2 |
| Letter of authorisation | Legalised copy of the manufacturer’s letter of authorisation | Article 5.1.7 |
| Language and legalisation | Translation by a local sworn translator; foreign documents complete statutory legalisation | Articles 5.2.4, 5.2.5 |
| Classification determination | Devices per Annex 1; reagents per NT 40 Article 3 | Annex 1; NT 40 Article 3 |
| Changes and renewal | Ten categories of change under Article 6; four renewal documentation items under Article 9 | Articles 6, 9 |
| Import | Import licence procedure | NT 26-2016, Versión 3-2017 |
3. Expert insights
Insight 1: The licensed local partner is not an optional step but a statutory condition. Article 5.1.13 requires the registration holder to hold a domestic establishment sanitary licence, and Article 5.1.2 requires the signature of a locally practising professional. A foreign manufacturer cannot satisfy these by itself, so the combined model is the only viable route rather than a service wrapper. What remains in the company’s control is the choice of partner and the definition of the interface between the parties, and both of these decisions benefit from being made before the dossier work starts rather than alongside it, because the partner’s licence details appear in the filing itself.
Insight 2: The division of the interface determines the controllability of the project. Placing dossier preparation, qualitative determination and progress management with the own team preserves technical quality and consistency across multiple countries; placing registration holder eligibility and local signatures with the partner satisfies the statutory formalities. When the interface is clear, responsibility can be located quickly when problems arise, and neither side’s work product depends on the other’s undocumented assumptions. In practice this means the written division of duties should cover not only who prepares each document but who signs it, who submits it and who answers authority queries about it.
Insight 3: Classification determination is the step where the combined model delivers the highest value. Guatemala’s classification axes (use × sterility) and the three-tier risk scheme for reagents are easily misread, and this determination cascades into testing obligations, sample preparation and the depth of documentation. Having it completed up front by a team that can verify the official texts avoids wholesale rework later in the project, when corrections are far more expensive. A wrong classification discovered after submission touches the testing plan, the sample quantities and the dossier structure at once, which is why this step is treated as a gate in the project plan rather than a formality on the way to submission.
Insight 4: The 2026 new regulation makes the local information channel more necessary within the combined model. G/TBT/N/GTM/106 is proposed to take effect on 2026-12-01 and repeal 712-99, and official information on transitional arrangements will come mainly from the DRCPFA and the official gazette. During the transition, the value of the local partner’s information channel is higher than in ordinary periods, because local-language sources surface changes earlier than monitoring conducted from outside the country, and transitional clarifications are often issued first through local channels before they reach international compilations.
4. Practical recommendations
- At project start, confirm in parallel the type and validity period of the local partner’s establishment sanitary licence.
- Complete the classification determination before documentation preparation and issue a written determination report.
- Issue the letter of authorisation in favour of the registration holder, with scope covering registration, changes and renewal.
- Keep the authorisation and the distribution agreement separate, so that channel changes do not drag on the registration asset.
- For transition-period projects, establish dual-channel monitoring of the official gazette and DRCPFA announcements.
5. Verification checklist
- □ Establishment sanitary licence of the local partner verified
- □ Classification determination report issued before documentation preparation
- □ Letter of authorisation issued in favour of the registration holder with complete scope
- □ Authorisation and distribution agreement kept separate
- □ Dual-channel monitoring of the gazette and DRCPFA established
- □ Responsibility interface among the parties confirmed in writing
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us